Grants and Contributions:
Title:
Efficacy testing of lead ocular compound
Agreement Number:
964084
Agreement Value:
$50,000.00
Agreement Date:
Jan 15, 2021 - Mar 31, 2021
Description:
The project will involve conducting proof of concept in vivo efficacy and isolation of an optically pure lead compound to support development of a novel therapeutic as a potential treatment for certain sight-threatening ocular inflammatory disorders.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5Z 1K5
Reference Number:
172-2020-2021-Q4-964084
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
818181224
Recipient Type:
For-profit organization
Recipient's Legal Name:
Naegis Pharmaceuticals Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710